Monte Rosa Therapeutics is rated a risky Buy due to its reliance on the clinical success of MRT-6160, a drug targeting autoimmune diseases. The company’s lead asset offers oral convenience and differentiated safety, with Phase 2 trial results expected to be a key catalyst. Monte Rosa holds a strong cash position of $626 million, providing a 3.5-year financial runway to support ongoing clinical expenses. The current share price is slightly below its risk-adjusted fair value, with potential for significant upside if MRT-6160 succeeds in trials.
Baidu announced that its Class A ordinary shares listed on the Hong Kong Stock Exchange will be included in the Shanghai-Hong Kong Stock Connect program starting September 7, 2026. This inclusion allows eligible mainland Chinese investors to directly...
Curaleaf Holdings has opened a new cannabis dispensary in Riverview, Florida, marking its 77th location in the state and 178th across the U.S. This expansion reflects Curaleaf's strategy to grow its presence in Florida's fast-growing medical cannabis...
SpaceX's stock currently trades below its first closing price despite a strong IPO debut, with a consensus analyst target price about 48% higher than the current price. Raymond James analyst Brian Gesuale projects a much more optimistic outlook, sett...
Critical Metals has consolidated 92.5% ownership of the Tanbreez heavy rare earths project and secured a 15-year offtake agreement with REalloys. The company has started a 10,000-meter drilling program to better define its resources. Tanbreez stands ...
Xcel Energy declared a quarterly dividend of $0.5925 per share, continuing its streak of annual dividend increases aligned with its 4%-6% raise policy. The company operates as a regulated utility, providing predictable cash flows supported by state-a...
